US EditionArtivion, Inc. (AORT) Investor Outlook: Potential Upside Of 25.43% And Strong Buy Ratings
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Artivion, Inc. (AORT) Investor Outlook: Potential Upside Of 25.43% And Strong Buy Ratings
Artivion, Inc. (NYSE: AORT), a prominent player in the healthcare sector, specifically within the medical devices industry, is capturing investor attention with a noteworthy potential upside of 25.43%. This Georgia-based company, with a market cap of $1.95 billion, specializes in manufacturing and distributing a variety of medical devices and implantable human tissues, making significant strides in the treatment of cardiovascular and vascular di…
Medical Device Network
Clinical Trials ArenaArtivion’s aortic stents boost post-surgical outcomes in interventional studies
Two of Artivion's aortic stents have displayed potential to improve outcomes post-surgery in patients who have experienced aortic aneurysms.The post Artivion’s aortic stents boost post-surgical outcomes in interventional studies appeared first on Medical Device Network.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
